A total of 11 clinical trials reveal a mixed effect of riboflavin in the prophylaxis of migraine headache. Five clinical trials show a consistent positive therapeutic effect in adults; four clinical trials show a mixed effect in pediatric and adolescent patients, and two clinical trials of combination therapy have not shown benefit. Adverse reactions with riboflavin have generally been mild. These studies show that riboflavin is well tolerated, inexpensive and has
demonstrated efficacy in the reduction of adult patient’s migraine headache frequency. Additional data is needed, however, to resolve questions involving pharmacokinetic issues and pharmacogenomic implications of therapy.
Marashly, E. T., & Bohlega, S. A. (2017). Riboflavin Has Neuroprotective Potential: Focus on Parkinson’s Disease and Migraine. Frontiers in neurology, 8, 333. https://doi.org/10.3389/fneur.2017.00333